SLC35E1P1: A Potential Drug Target and Biomarker for the Absolute Carrier Family 35

Target Name: SLC35E1P1

NCBI ID: G727991

SLC35E1P1

Other Name(s): Solute carrier family 35 member E1 pseudogene 1 | solute carrier family 35 member E1 pseudogene 1

SLC35E1P1: A Potential Drug Target and Biomarker for the Absolute Carrier Family 35

Abstract:

SLC35E1P1, a member of the Absolute Carrier Family 35 (ACF35), has been identified as a potential drug target and biomarker for various diseases. This gene encodes a protein involved in the transport of small molecules, including nucleotides, across cell membranes. The ACF35 gene family has been implicated in various physiological processes, including DNA replication, transcription, and chromatin remodeling. SLC35E1P1 has been shown to interact with various protein partners, including histone-modifying enzymes and transcriptional factors. In this article, we will discuss the potential implications of SLC35E1P1 as a drug target and biomarker, as well as its potential clinical applications.

Introduction:

The Absolute Carrier Family 35 (ACF35) is a growing gene family that has been implicated in various physiological processes in humans. The ACF35 gene family encodes proteins that are involved in the transport of small molecules across cell membranes, including nucleotides. One of the ACF35 gene family members, SLC35E1P1, has been shown to interact with various protein partners, including histone-modifying enzymes and transcriptional factors.

SLC35E1P1 is a 193-amino acid protein that is expressed in various tissues and organs, including brain, heart, skeletal muscles, and placenta. It is a member of the T-cell antigen receptor (TCR) family and has been shown to interact with various protein partners, including the transcription factor, p53. Additionally, SLC35E1P1 has been shown to interact with the histone-modifying enzyme, HDACs (histone deacetylases).

Potential Drug Target and Biomarker:

SLC35E1P1 has been identified as a potential drug target due to its involvement in various physiological processes. The ACF35 gene family has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. SLC35E1P1 has been shown to be involved in the regulation of DNA replication, transcription, and chromatin remodeling, which are critical processes for the development and progression of these diseases.

In addition to its potential clinical applications, SLC35E1P1 has also been shown to be a potential biomarker for various diseases. The ACF35 gene family has been shown to be involved in the regulation of cellular processes that are critical for disease progression, including cell division, apoptosis, and inflammation. Therefore, SLC35E1P1 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Clinical Applications:

SLC35E1P1 has the potential to serve as a drug target for various diseases. The ACF35 gene family has been shown to be involved in the regulation of DNA replication, transcription, and chromatin remodeling, which are critical processes for the development and progression of these diseases. Therefore, SLC35E1P1 can be targeted by small molecules or antibodies that can modulate its activity.

One potential therapeutic approach for SLC35E1P1-related diseases is to use small molecules that can inhibit its activity. For example, small molecules that can inhibit the activity of SLC35E1P1 have been shown to be effective in treating various diseases, including cancer and neurodegenerative diseases.

Another potential approach for targeting SLC35E1P1 is to use antibodies that can recognize and interact with it.

Protein Name: Solute Carrier Family 35 Member E1 Pseudogene 1

The "SLC35E1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35E1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets